INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE.
SOUTH SAN FRANCISCO, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE...
First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasisTopline data from Phase 1 clinical trial of second oral IL-17 inhibitor,...
SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology...
DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting
DICE Therapeutics to Participate at Upcoming Investor Conferences